Go back and read my other post where I clearly said: "Ken may have signed the initial papers with the intent to acquire it, but clearly wasn't in the drivers seat throughout the actual acquisition." You're confusing a purchase agreement with the actual acquisition. Anyone who works at an executive level knows the CEO isn't responsible for identifying new opportunities. The head of Business Development, in this case Nader, is the one who clearly identified PRO 140 as the path forward for the company, and the CEO agreed by signing the purchase agreement and then stepping down to allow Nader to fill his role. After all, as 3X said, Ken's expertise was Real Estate. I know it's painful for the 13Der's to admit this, but they cannot revise 9 years of history, especially when everyone already knows how and who rescued PRO 140 from the shelf. Prior to the 13D filing, NOBODY claimed it was Ken. If Ken had identified PRO 140 as the future, he wouldn't have signed the purchase agreement and then immediately stepped down so the Board could replace him with Nader to drive the acquisition and move the ball forward. That's laughable.
"You said Ken was CEO and deserved credit for rescuing PRO-140 from the shelf, yet it was Nader who was CEO when it was acquired. Now Ken may have signed the initial papers with the intent to acquire it, but clearly wasn't in the drivers seat throughout the actual acquisition. Additionally, as you mentioned below, Ken's area of expertise was real estate, which explains why he stepped down to let to Nader take the lead, especially given that Nader was the Managing Director of "Business Development" and obviously who would have been responsible for new business initiatives. As you should know, CEO's hire good business development talent who are are responsible for identifying new opportunities, and the CEOs normally follow their lead.
"Prior to his new position as CEO, Dr. Pourhassan served as the Company’s Managing Director of Business Development, and before that, as its Chief Operating Officer."
“CytoDyn is a company focused on the development of monoclonal antibodies for the treatment of immune deficiency viruses. Pro 140 is the most advanced cell-specific monoclonal antibody to date being tested for the treatment of HIV. This makes it a perfect fit for our company. We believe that Pro 140 represents an entirely new approach to treating HIV. We are excited about taking it forward through the next stages of clinical development,” said Dr. Nader Pourhassan, CytoDyn’s interim President and CEO." https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165780498
News 
Market Data 
Discover 
AI
